Pharming Group N.V. reported $376M of revenue over the trailing twelve months, +27% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $376M (to FY2025). Net income: $2.5M, trailing twelve months to FY2025. Free cash flow: $54M, trailing twelve months to FY2025. Operating margin: 6.9%, trailing twelve months to FY2025.

PHARPharming Group N.V.

Healthcare

$9.70-34% 1Y

$9.70

$9.7052 weeks$21.18

PHAR as reported

Pharming Group N.V. reported $376M of revenue over the trailing twelve months, +27% on the year before. 9 reported series are charted on this page, each one as filed.

$376M

Revenue, trailing twelve months · to FY2025 · +27% against the twelve months before

Net income: $2.5M
Net income · −121% year on year · trailing twelve months to FY2025
Free cash flow: $54M
Free cash flow · −2187% year on year · trailing twelve months to FY2025
Operating margin: 6.9%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for PHAR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$376M	+27%	FY2025
Net income	$2.5M	−121%	FY2025
EPS	$0.00	−122%	FY2025
Gross margin	88%	n/a	FY2025
Operating margin	6.9%	n/a	FY2025
Net margin	0.67%	n/a	FY2025
ROE	0.92%	n/a	FY2025
ROA	0.51%	n/a	FY2025
Free cash flow	$54M	−2187%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.